Nanobiotix will take stock of ASCO

Posted 03 May, 2022

At the next congress of the American Society of Clinical Oncoly (ASCO), a major annual meeting for clinical research and innovation in oncology, Nanobiotix will provide an update on its preclinical and clinical developments in various solid tumors and therapeutic combinations: presentation of very promising results from an unprecedented phase II study in rectal cancer. Nanobiotix will also review progress from the ongoing global Phase III study in high-risk elderly patients with locally advanced head and neck cancer.

Nanobiotix is ​​currently conducting a dozen clinical trials, worldwide, in cooperation with, in particular, the Institut Curie, the Gustave Roussy Institute, and the MD Anderson Cancer Center (United States).

GLOSSARY
Clinical trials (Phases I, II, III)
Phase I: small-scale testing of the molecule on humans to assess its safety, tolerance, metabolic and pharmacological properties.

Phase II: evaluation of tolerance and efficacy on several hundred patients to identify side effects.

Phase III: evaluation of the overall benefit/risk ratio with several thousand patients.

Previous story

03 May, 2022 10:09

← BP: huge quarterly loss with the exit from Russia

BP reports results that beat analysts' expectations in the first quarter while recording a huge charge related to its exit from Russia of $29.3 billion.

BP: huge quarterly loss with the exit from Russia

Next story

02 May, 2022 09:37

Qantas: direct flights from Sydney to London and New York by the end of 2025 →

Australian airline Qantas announced on Monday that it will launch the world's first non-stop commercial flights linking Sydney with London and New York by the end of 2025.

Qantas: direct flights from Sydney to London and New York by the end of 2025
Write a comment
 
Prove you’re not a bot + 10 = 16